BMS-191011 | CAS#202821-81-6 | Calcium-Activated Potassium (KCa) Channel Activator |MedKoo

BMS-191011
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524445

CAS#: 202821-81-6

Description: BMS 191011 is a potent KCa1.1 (BK) channel opener. It is also neuroprotectant in two distinct animal models of stroke- MCAO in the SHR rat and a normotensive model of focal stroke.

Chemical Structure

BMS-191011

CAS# 202821-81-6

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 524445
Name: BMS-191011
CAS#: 202821-81-6
Chemical Formula: C16H10ClF3N2O3
Exact Mass: 370.03
Molecular Weight: 370.710
Elemental Analysis: C, 51.84; H, 2.72; Cl, 9.56; F, 15.37; N, 7.56; O, 12.95

Price and Availability

Size	Price	Availability
10mg	USD 150	Ready to ship
25mg	USD 250	Ready to ship
50mg	USD 450	Ready to ship
100mg	USD 750	Ready to ship
200mg	USD 1250	Ready to ship
500mg	USD 2150	Ready to ship
1g	USD 2950	Ready to ship
2g	USD 5150	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: BMS-191011; BMS 191011; BMS191011; UNII-LW7MXS978N; Bms-a.

IUPAC/Chemical Name: 1,3,4-Oxadiazol-2(3H)-one, 3-((5-chloro-2-hydroxyphenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-

InChi Key: QKOWACXSXTXRKA-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H10ClF3N2O3/c17-12-5-6-13(23)10(7-12)8-22-15(24)25-14(21-22)9-1-3-11(4-2-9)16(18,19)20/h1-7,23H,8H2

SMILES Code: c1cc(ccc1c2nn(c(=O)o2)Cc3cc(ccc3O)Cl)C(F)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#A21T06K03

QC Data:

View QC data: current batch, Lot#A21T06K03

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	BMS-191011 (BMS-A) is an opener of the large-conductance, Ca2+-activated potassium (maxi-K) channel, effective in stroke models.
In vitro activity:
In vivo activity:	The effects of BMS-191011 was examined openers of BK(Ca) channels, on rat retinal blood vessels in vivo. Male Wistar rats (8- to 10-week-old) were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally (i.p.)) and treated with tetrodotoxin (50 µg/kg, intravenously (i.v.)) to eliminate any nerve activity and prevent movement of the eye under artificial ventilation. A mixture solution of adrenaline and noradrenaline (9:1) was infused to maintain adequate systemic circulation. BMS-191011 (10-100 µg/kg, i.v.) increased the diameter of retinal arterioles without altering systemic blood pressure and heart rate significantly. The vasodilator responses to BMS-191011 were significantly diminished by intravitreal injection of iberiotoxin (an inhibitor of BK(Ca) channels, 20 pmol/eye). These results suggest that BMS-191011 dilates rat retinal arterioles through activation of iberiotoxin-sensitive BK(Ca) channels in vivo. The BK(Ca) channel opener could be considered as a candidate for improving retinal circulation without severe cardiovascular side-effects. Reference: Biol Pharm Bull. 2011;34(1):150-2. http://joi.jlc.jst.go.jp/JST.JSTAGE/bpb/34.150?from=PubMed

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	20.0	54.00

Preparing Stock Solutions

The following data is based on the product molecular weight 370.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:	1. Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo. Biol Pharm Bull. 2011;34(1):150-2. doi: 10.1248/bpb.34.150. PMID: 21212534.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Levin SG, Konakov MV, Godukhin OV. Role of BKCa Potassium Channels in the Mechanisms of Modulatory Effects of IL-10 on Hypoxia-Induced Changes in Activity of Hippocampal Neurons. Bull Exp Biol Med. 2016 Mar;160(5):643-5. doi: 10.1007/s10517-016-3238-0. Epub 2016 Mar 29. PubMed PMID: 27021102.

2: Ji F, Li X, Guo W, Wu W, Jiang H. Palladium-Catalyzed Oxidative O-H/N-H Carbonylation of Hydrazides: Access to Substituted 1,3,4-Oxadiazole-2(3H)-ones. J Org Chem. 2015 Jun 5;80(11):5713-8. doi: 10.1021/acs.joc.5b00664. Epub 2015 May 20. PubMed PMID: 25973639.

3: Mori A, Takei T, Sakamoto K, Nakahara T, Ishii K. 4-Hydroxy-2-nonenal attenuates β2-adrenoceptor-mediated vasodilation of rat retinal arterioles. Naunyn Schmiedebergs Arch Pharmacol. 2015 May;388(5):575-82. doi: 10.1007/s00210-015-1099-0. Epub 2015 Feb 19. PubMed PMID: 25693977.

4: Shukla P, Ghatta S, Dubey N, Lemley CO, Johnson ML, Modgil A, Vonnahme K, Caton JS, Reynolds LP, Sun C, O'Rourke ST. Maternal nutrient restriction during pregnancy impairs an endothelium-derived hyperpolarizing factor-like pathway in sheep fetal coronary arteries. Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H134-42. doi: 10.1152/ajpheart.00595.2013. Epub 2014 May 9. PubMed PMID: 24816259; PubMed Central PMCID: PMC4101639.

5: Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. Vasodilation of retinal arterioles induced by activation of BKCa channels is attenuated in diabetic rats. Eur J Pharmacol. 2011 Nov 1;669(1-3):94-9. doi: 10.1016/j.ejphar.2011.07.042. Epub 2011 Aug 19. PubMed PMID: 21871885.

6: Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo. Biol Pharm Bull. 2011;34(1):150-2. PubMed PMID: 21212534.

7: Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. Role of calcium-activated potassium channels in acetylcholine-induced vasodilation of rat retinal arterioles in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jan;383(1):27-34. doi: 10.1007/s00210-010-0570-1. Epub 2010 Oct 27. PubMed PMID: 20978884.

8: Romine JL, Martin SW, Meanwell NA, Gribkoff VK, Boissard CG, Dworetzky SI, Natale J, Moon S, Ortiz A, Yeleswaram S, Pajor L, Gao Q, Starrett JE Jr. 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR. J Med Chem. 2007 Feb 8;50(3):528-42. PubMed PMID: 17266205.

9: Hewawasam P, Ding M, Chen N, King D, Knipe J, Pajor L, Ortiz A, Gribkoff VK, Starrett J. Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection. Bioorg Med Chem Lett. 2003 May 19;13(10):1695-8. PubMed PMID: 12729644.

Your view history

BMS-191011 new featured